Press release
Antibody Drug Conjugate Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration by DelveInsight | ImmunoGen, Seagen, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA
Antibody Drug Conjugate Clinical Trials
Key Takeaways from the Antibody Drug Conjugate Pipeline Report
• DelveInsight's Antibody Drug Conjugate pipeline report depicts a robust space with 180+ active players working to develop 290+ pipeline therapies for Antibody Drug Conjugate treatment.
• The leading companies working in the Antibody Drug Conjugate Market include NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
• Promising Antibody Drug Conjugate Pipeline Therapies in the various stages of development include Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.
• December 2023: Unicancer announced a drug which is named DS-8201a in the clinical trials of phase 2. Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.
• December 2023: Daiichi Sankyo Inc. announced a drug which is named Ifinatamab Deruxtecan (I-DXd) in the clinical trials of phase 2. This study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platinum-based chemotherapy and a maximum 3 prior lines of therapy and to investigate I-DXd anti-tumor activity in this population.
Request a sample and discover the recent advances in Antibody Drug Conjugate Drugs @ Antibody Drug Conjugate Competitive Landscape Report- https://www.delveinsight.com/report-store/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Antibody Drug Conjugate Pipeline Report provides in-depth commercial assessment of ADC drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Antibody Drug Conjugate Overview
Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine an antibody specific to cancer cells with a potent cytotoxic drug. This design allows the selective delivery of the drug to cancer cells, minimizing damage to healthy tissues. The antibody component binds to antigens on the surface of cancer cells, and once bound, the ADC is internalized and the cytotoxic drug is released inside the cell, leading to cell death.
ADCs consist of three main components: the antibody, the linker, and the cytotoxic drug. The antibody ensures specificity by targeting cancer cell antigens. The linker, which can be cleavable or non-cleavable, attaches the drug to the antibody and ensures its stable delivery to the target site. The cytotoxic drug, often referred to as the payload, is typically a highly potent agent that can kill cancer cells even at low concentrations.
ADCs offer a promising approach for cancer treatment, providing the precision of targeted therapy with the potency of chemotherapy. Recent advancements in ADC technology have led to the development of several FDA-approved ADCs for various cancers, and ongoing research continues to enhance their efficacy, safety, and applicability to a broader range of malignancies.
Find out more about Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment @ Antibody Drug Conjugate Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Antibody Drug Conjugate Pipeline Therapies and Companies
• Jiangsu Hengrui Medicine Co Ltd.: SHR-A1811
• Seagen Inc.: Ladiratuzumab Vedotin
• ImmunoGen Inc.: IMGN151
• Daiichi Sankyo: DS-6000
Antibody Drug Conjugate Pipeline Analytical Perspective
The Antibody Drug Conjugate pipeline report provides in-depth commercial assessment of Antibody Drug Conjugate drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Antibody Drug Conjugate Pipeline Report Assessment
• Antibody Drug Conjugate Company Analysis
• Antibody Drug Conjugate Pipeline Therapeutic Assessment
• Antibody Drug Conjugate Pipeline Assessment
• Inactive Antibody Drug Conjugate drugs assessment
• Antibody Drug Conjugate Unmet Needs
Learn more about the emerging Antibody Drug Conjugate Competitive Landscape @ Antibody Drug Conjugate Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Antibody Drug Conjugate Competitive Landscape Report
• Coverage- Global
• Antibody Drug Conjugate Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• Antibody Drug Conjugate Companies- NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
• Antibody Drug Conjugate Pipeline Therapies- Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.
Dive deep into rich insights for new drugs for Antibody Drug Conjugate Product Developmental Activities, Visit @ Antibody Drug Conjugate Research and Development Activities- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Antibody Drug Conjugate Executive Summary
3. Antibody Drug Conjugate Overview
4. Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment
5. Antibody Drug Conjugate Competitive Landscape
6. Antibody Drug Conjugate Therapeutic Assessment
7. Antibody Drug Conjugate: Company and Product Profiles (Marketed Therapies)
8. Pfizer
9. MYLOTARG
10. Antibody Drug Conjugate: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. ADC Therapeutics
13. Zynlonta
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Seagen Inc.
17. Ladiratuzumab Vedotin
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. ImmunoGen, Inc.
21. IMGN151
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Antibody Drug Conjugate - Unmet needs
29. Antibody Drug Conjugate- Market drivers and barriers
30. Appendix
For further information on the Antibody Drug Conjugate Report @ Antibody Drug Conjugate Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Advanced Recurrent Ovarian Cancer Market: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Alkaptonuria Market: https://www.delveinsight.com/report-store/alkaptonuria-market
• Anti-gbm Market: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights
• Cancer Anorexia Market: https://www.delveinsight.com/blog/cancer-anorexia-market
• Chronic Rhinosinusitis Phenotype With Nasal Polyps Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-phenotype-with-nasal-polyps-market-insight
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
• Hyperopia Market: https://www.delveinsight.com/report-store/hyperopia-market
• Nonmuscle Invasive Bladder Cancer Market: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
• Oral Mucositis Om Market: https://www.delveinsight.com/report-store/oral-mucositis-om-market
• Severe Hypertriglyceridemia Market: https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Bk Virus Infection Market: https://www.delveinsight.com/report-store/bk-virus-bkv-infection-market
• Human Papillomavirus Positive Cancer Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Intrahepatic Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antibody-mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Bone And Joint Infection Market: https://www.delveinsight.com/report-store/prosthetic-joint-infection-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Cardiorenal Syndrome Market: https://www.delveinsight.com/report-store/cardiorenal-syndrome-market
• Facioscapulohumeral Muscular Dystrophy Market: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
• Menorrhalgia Market: https://www.delveinsight.com/report-store/menorrhalgia-market
• Postmenopausal Vaginal Atrophy Market: https://www.delveinsight.com/infographics/atrophic-vaginitis-market
• Uncomplicated Urinary Tract Infections Market: https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market
• Balloon Catheters Market: https://www.delveinsight.com/report-store/balloon-catheters-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Cutaneous Lupus Erythematosus Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Vascular Dementia Market: https://www.delveinsight.com/report-store/vascular-dementia-market
• West Syndrome Market: https://www.delveinsight.com/report-store/west-syndrome-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody Drug Conjugate Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration by DelveInsight | ImmunoGen, Seagen, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA here
News-ID: 3611869 • Views: …
More Releases from DelveInsight Business Research
Sarcoidosis Treatment Market 2032: FDA Approval, Clinical Trials, Prevalence, Th …
DelveInsight's "Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Sarcoidosis, historical and forecasted epidemiology as well as the Sarcoidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Sarcoidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sarcoidosis Market Forecast
https://www.delveinsight.com/sample-request/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of the Sarcoidosis Market Report:
•…
Chronic Spontaneous Urticaria Treatment Market 2034: FDA Approval, Clinical Tria …
DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Spontaneous Urticaria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Spontaneous Urticaria Market…
Chronic Lower Back Pain Treatment Market 2032: FDA Approval, Clinical Trials, Ma …
(Albany, USA) DelveInsight's "Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Lower Back Pain, historical and forecasted epidemiology as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Lower Back Pain market outlook, drug uptake, treatment scenario and epidemiology trends,…
Non-Small Cell Lung Cancer (NSCLC) Clinical Trials 2024: EMA, PDMA, FDA Approval …
(Albany, USA) DelveInsight's, "Non-Small-Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 135+ Non-Small Cell Lung Cancer Companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It…
More Releases for Drug
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…
